OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Reviews is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	117
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	116
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	115
Editorial Board	107
Not all LGL leukemias are created equal	78
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	66
Clinical burden of hemophilia in older adults: Beyond bleeding risk	58
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	56
Radiation and leukaemia: Which leukaemias and what doses?	53
Artificial intelligence in sickle disease	53
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	51
Thalassaemia in China	47
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	45
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	40
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	38
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	38
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	38
Chasing leukemia differentiation through induction therapy, relapse and transplantation	37
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	37
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	36
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	36
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	36
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	34
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	33
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	33

CHIPing away the progression potential of CHIP: A new reality in the making	33
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	32
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	31
Endothelial cells: major players in acute myeloid leukaemia	31
Immune thrombocytopenia: A review of upfront treatment strategies	31
Preservation of fertility in female patients with hematologic diseases	31